Blog
RSS FeedPosted by Michael Wonder on 03 May 2024
Improved deal signals NICE recommendation of sickle cell treatment voxelotor
3 May 2024 - Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE ...
Posted by Michael Wonder on 03 May 2024
Agenda for the May 2024 PBAC meeting
3 May 2024 - The agenda for next week's PBAC meeting is now available. ...
Posted by Michael Wonder on 03 May 2024
NHS rolls out ‘life-changing’ treatment for thousands with sickle cell disease
3 May 2024 - Thousands of patients with sickle cell disorder are to be offered a new “life-changing” treatment on ...
Posted by Michael Wonder on 02 May 2024
CADTH is now Canada’s Drug Agency
1 May 2024 - As of today, we will adopt Canada’s Drug Agency (CDA-AMC) as our new operating name. ...
Posted by Michael Wonder on 02 May 2024
PHARMAC publishes agenda from the 15-16 February 2024 PTAC meeting
1 May 2024 - The outcomes from the February 2024 PTAC meeting are now available. ...
Posted by Michael Wonder on 01 May 2024
Selpercatinib for the treatment of patients with advanced thyroid cancer with RET alterations that has not been treated with systemic therapy
1 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 May 2024
Pembrolizumab for the treatment of patients 3 years and older with relapsed or refractory classical Hodgkin's lymphoma
1 May 2024 - NICE has published updated evidence-based recommendations on the pembrolizumab (Keytruda) for the treatment of patients with ...
Posted by Michael Wonder on 30 Apr 2024
Gefapixant for the treatment of patients with refractory or unexplained chronic cough
30 April 2024 - NICE is unable to make a recommendation on the use of gefapixant (Lyfnua) for the treatment of ...
Posted by Michael Wonder on 29 Apr 2024
Idebenone for the treatment of patients 12 years and older with visual impairment associated with Leber’s hereditary optic neuropathy
24 April 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Apr 2024
Life prolonging breast cancer drug recommended for PBS subsidy, but it is not time to celebrate
26 April 2024 - Breast Cancer Network Australia (BCNA) today welcomed a decision by the PBAC to recommend the life ...
Posted by Michael Wonder on 28 Apr 2024
Former Deputy Prime Minister Paula Bennett appointed new chair of PHARMAC
28 April 2024 - Former Deputy Prime Minister Paula Bennett has been appointed the new chair of the national drug ...
Posted by Michael Wonder on 26 Apr 2024
Recommendations made by the PBAC (March 2024)
26 April 2024 - Recommendations made by the PBAC in March 2024 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 26 Apr 2024
Melphalan flufenamide hydrochloride in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
25 April 2024 - NICE is unable to make a recommendation on the use of melphalan flufenamide hydrochloride (Pepaxti) in combination ...
Posted by Michael Wonder on 25 Apr 2024
Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment
24 April 2024 - A new targeted drug combination treatment, described as a ‘step-change in care’ for children and young ...
Posted by Michael Wonder on 24 Apr 2024
Pembrolizumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with advanced biliary tract cancer
24 April 2024 - NICE is unable to make a recommendation on the use of pembrolizumab (Keytruda) in combination with cisplatin ...